BridgeBio Pharma, Inc.
NASDAQ:BBIO
25.2 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 9.303 | 77.648 | 69.716 | 8.249 | 40.56 | 0 | 0 |
| Cost of Revenue
| 2.446 | 3.434 | 3.114 | 3.088 | 2.5 | 0 | 0.26 |
| Gross Profit
| 6.857 | 74.214 | 66.602 | 5.161 | 38.06 | 0 | -0.26 |
| Gross Profit Ratio
| 0.737 | 0.956 | 0.955 | 0.626 | 0.938 | 0 | 0 |
| Reseach & Development Expenses
| 455.711 | 402.896 | 454.138 | 337.047 | 209.947 | 140.073 | 30.556 |
| General & Administrative Expenses
| 0 | 0 | 0 | 145.684 | 94.353 | 43.587 | 13.302 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 150.59 | 143.189 | 192.21 | 145.684 | 94.353 | 43.587 | 13.302 |
| Other Expenses
| 0.27 | 100.446 | 35.823 | 1.634 | -1.21 | -1.291 | 0 |
| Operating Expenses
| 606.301 | 546.085 | 646.348 | 482.731 | 304.3 | 183.66 | 43.858 |
| Operating Income
| -607.37 | -471.871 | -579.746 | -474.482 | -266.24 | -183.66 | -43.858 |
| Operating Income Ratio
| -65.288 | -6.077 | -8.316 | -57.52 | -6.564 | 0 | 0 |
| Total Other Income Expenses Net
| 9.444 | -12.781 | -6.708 | -31.006 | -22.345 | 14.752 | 0.026 |
| Income Before Tax
| -653.251 | -484.652 | -586.454 | -505.488 | -288.585 | -169.451 | -43.832 |
| Income Before Tax Ratio
| -70.219 | -6.242 | -8.412 | -61.279 | -7.115 | 0 | 0 |
| Income Tax Expense
| 71.51 | 9.312 | 52.843 | -21.563 | -28.148 | 16.756 | -13.488 |
| Net Income
| -643.202 | -493.964 | -639.297 | -483.925 | -260.437 | -130.749 | -30.565 |
| Net Income Ratio
| -69.139 | -6.362 | -9.17 | -58.665 | -6.421 | 0 | 0 |
| EPS
| -3.95 | -3.35 | -4.43 | -4.1 | -2.48 | -1.42 | -0.33 |
| EPS Diluted
| -3.95 | -3.35 | -4.43 | -4.1 | -2.48 | -1.42 | -0.33 |
| EBITDA
| -574.642 | -353.678 | -539.676 | -468.833 | -279.404 | -182.977 | -43.819 |
| EBITDA Ratio
| -61.77 | -4.555 | -7.741 | -56.835 | -6.889 | 0 | 0 |